New SARS-CoV-2 Variant Spreading Rapidly in UK

The significance of the variant remains unclear, but experts remain confident that it will not evade the protection offered by a COVID-19 vaccine.

Written byMax Kozlov
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Update (December 21): More than 40 countries have restricted UK arrivals while experts continue to investigate the implications of the variant. Oxford University epidemiologist Peter Horby, who chairs the UK New and Emerging Respiratory Virus Threats Advisory Group, tells a Science Media Centre briefing on Monday, “We now have high confidence that this variant does have a transmission advantage.” Despite the new findings, epidemiologists tell The New York Times that mutations are to be expected and that it would take a matter of years, not months, for a strain to evolve enough to render the current vaccines ineffective.

ABOVE: © ISTOCK.COM,
TOLGART

As public health officials worldwide mount vaccination campaigns against COVID-19, a new SARS-CoV-2 variant has rapidly taken hold in the UK, leading scientists to investigate if it carries any implications for the transmissibility of the virus, severity of infection, and success of a vaccine, though experts say it is ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Max is a science journalist from Boston. Though he studied cognitive neuroscience, he now prefers to write about brains rather than research them. Prior to writing for The Scientist as an editorial intern in late 2020 and early 2021, Max worked at the Museum of Science in Boston, where his favorite part of the job was dressing in a giant bee costume and teaching children about honeybees. He was also a AAAS Mass Media Fellow, where he worked as a science reporter for the St. Louis Post-Dispatch. Read more of his work at www.maxkozlov.com.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies